AAAAAA
Results:
1-22
|
Results: 22
Authors:
Pingpank, JF
Hoffman, JP
Ross, EA
Cooper, HS
Meropol, NJ
Freedman, G
Pinover, WH
LeVoyer, TE
Sasson, AR
Eisenberg, BL
Citation: Jf. Pingpank et al., Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas, J GASTRO S, 5(2), 2001, pp. 121-130
Authors:
von Mehren, M
Arlen, P
Gulley, J
Rogatko, A
Cooper, HS
Meropol, NJ
Alpaugh, RK
Davey, M
McLaughlin, S
Beard, MT
Tsang, KY
Schlom, J
Weiner, LM
Citation: M. Von Mehren et al., The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma, CLIN CANC R, 7(5), 2001, pp. 1181-1191
Authors:
Clapper, ML
Chang, WCL
Meropol, NJ
Citation: Ml. Clapper et al., Chemoprevention of colorectal cancer, CURR OPIN O, 13(4), 2001, pp. 307-313
Authors:
Rothenberg, ML
Meropol, NJ
Poplin, EA
Van Cutsem, E
Wadler, S
Citation: Ml. Rothenberg et al., Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel, J CL ONCOL, 19(18), 2001, pp. 3801-3807
Authors:
Meropol, NJ
Sonnichsen, DS
Birkhofer, MJ
Ferreira, I
Noel, D
Citation: Nj. Meropol et al., Bioavailability and phase II study of oral UFT plus leucovorin in patientswith relapsed or refractory colorectal cancer (vol 43, pg 221, 1999), CANC CHEMOT, 47(3), 2001, pp. 282-282
Authors:
Mandelblatt, JS
Berg, CD
Meropol, NJ
Edge, SB
Gold, K
Hwang, YT
Hadley, J
Citation: Js. Mandelblatt et al., Measuring and predicting surgeons' practice styles for breast cancer treatment in older women, MED CARE, 39(3), 2001, pp. 228-242
Authors:
Carson, WE
Parihar, R
Lindemann, MJ
Personeni, N
Dierksheide, J
Meropol, NJ
Baselga, J
Caligiuri, MA
Citation: We. Carson et al., Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells, EUR J IMMUN, 31(10), 2001, pp. 3016-3025
Authors:
Meropol, NJ
Niedzwiecki, D
Hollis, D
Schilsky, RL
Mayer, RJ
Citation: Nj. Meropol et al., Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma, CANCER, 91(7), 2001, pp. 1256-1263
Authors:
Sasson, AR
Hoffman, JP
Ross, E
Meropol, NJ
Szarka, CE
Freedman, G
Pinover, W
Pingpank, JF
Eisenberg, BL
Citation: Ar. Sasson et al., Trimodality therapy for advanced gallbladder cancer, AM SURG, 67(3), 2001, pp. 277-283
Authors:
Pendyala, L
Creaven, PJ
Schwartz, G
Meropol, NJ
Bolanowska-Higdon, W
Zdanowicz, J
Murphy, M
Perez, R
Citation: L. Pendyala et al., Intravenous ifosfamide/mesna is associated with depletion of plasma thiolswithout depletion of leukocyte glutathione, CLIN CANC R, 6(4), 2000, pp. 1314-1321
Authors:
Damjanov, N
Meropol, NJ
Citation: N. Damjanov et Nj. Meropol, Oral therapy for colorectal cancer: How to choose, ONCOLOGY-NY, 14(6), 2000, pp. 799-807
Authors:
Lewis, NL
Meropol, NJ
Citation: Nl. Lewis et Nj. Meropol, Oral fluoropyrimidines in cancer treatment, CANCER INV, 18(8), 2000, pp. 747-760
Authors:
Hensley, ML
Schuchter, LM
Winer, EP
Meropol, NJ
Pfister, D
Citation: Ml. Hensley et al., Dexrazoxane and the ASCO guidelines for the use of chemotherapy and radiotherapy protectants: A critique - In Reply, J CL ONCOL, 18(9), 2000, pp. 2005-2006
Authors:
Cheng, JD
Hitt, J
Koczwara, B
Schulman, KA
Burnett, CB
Gaskin, DJ
Rowland, JH
Meropol, NJ
Citation: Jd. Cheng et al., Impact of quality of life on patient expectations regarding phase I clinical trials, J CL ONCOL, 18(2), 2000, pp. 421-428
Authors:
Venook, AP
Egorin, MJ
Rosner, GL
Hollis, D
Mani, S
Hawkins, M
Byrd, J
Hohl, R
Budman, D
Meropol, NJ
Ratain, MJ
Citation: Ap. Venook et al., Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and leukemia group B 9565, J CL ONCOL, 18(14), 2000, pp. 2780-2787
Authors:
Ho, DH
Covington, W
Brown, N
Lin, SN
Pazdur, R
Huo, YY
Creaven, PJ
Rustum, YM
Meropol, NJ
Lassere, Y
Kuritani, J
Hayakawa, T
Citation: Dh. Ho et al., Oral uracil and Ftorafur plus leucovorin: pharmacokinetics and toxicity inpatients with metastatic cancer, CANC CHEMOT, 46(5), 2000, pp. 351-356
Authors:
Mandelblatt, JS
Hadley, J
Kerner, JF
Schulman, KA
Gold, K
Dunmore-Griffith, J
Edge, S
Guadagnoli, E
Lynch, JJ
Meropol, NJ
Weeks, JC
Winn, R
Citation: Js. Mandelblatt et al., Patterns of breast carcinoma treatment in older women - Patient preferenceand clinical and physician influences, CANCER, 89(3), 2000, pp. 561-573
Authors:
Cheng, JD
Werness, BA
Babb, JS
Meropol, NJ
Citation: Jd. Cheng et al., Paradoxical correlations of cyclin-dependent kinase inhibitors p21waf1/cip1 and p27kip1 in metastatic colorectal carcinoma, CLIN CANC R, 5(5), 1999, pp. 1057-1062
Authors:
Marcus, EA
Weber, TK
Rodriguez-Bigas, MA
Driscoll, D
Meropol, NJ
Petrelli, NJ
Citation: Ea. Marcus et al., Prognostic factors affecting survival in patients with colorectal carcinomatosis, CANCER INV, 17(4), 1999, pp. 249-252
Authors:
Meropol, NJ
Rustum, YM
Creaven, PJ
Blumenson, LE
Frank, C
Citation: Nj. Meropol et al., Phase I and pharmacokinetic study of weekly 5-fluorouracil administered with granulocyte-macrophage colony-stimulating factor and high-dose leucovorin: A potential role for growth factor as mucosal protectant, CANCER INV, 17(1), 1999, pp. 1-9
Authors:
Hensley, ML
Schuchter, LM
Lindley, C
Meropol, NJ
Cohen, GI
Broder, G
Gradishar, WJ
Green, DM
Langdon, RJ
Mitchell, B
Negrin, R
Szatrowski, TP
Thigpen, JT
Von Hoff, D
Wasserman, TH
Winer, EP
Pfister, DG
Citation: Ml. Hensley et al., American Society of Clinical Oncology clinical practice guidelines for theuse of chemotherapy and radiotherapy protectants, J CL ONCOL, 17(10), 1999, pp. 3333-3355
Authors:
Meropol, NJ
Sonnichsen, DS
Birkhofer, MJ
Ferreira, I
Noel, D
Citation: Nj. Meropol et al., Bioavailability and phase II study of oral UFT plus leucovorin in patientswith relapsed or refractory colorectal cancer, CANC CHEMOT, 43(3), 1998, pp. 221-226
Risultati:
1-22
|